Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors
Open accessThe DOI matches its Crossref record; 74 of the 77 references it cites were found in a registry or an index; none of the 86 sources its claims cite is checked for support yet.
Abstract
At least 45% of patients with type 2 diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One of the major contributing factors is poor medication adherence.
Overview
CoChat Summary
## TL;DR
This review argues that poor medication adherence in type 2 diabetes is common, often affecting at least half of patients, and is tied to worse glycemic control, higher costs, and higher mortality. It highlights two broad modifiable drivers: treatment burden and patients’ treatment-related beliefs.
## Key findings
- Reported poor medication adherence in T2D ranged from 38% to 93% across studies, largely because definitions and methods varied; using MPR ≥80%, adherence was 47.3% for dipeptidyl peptidase-4 inhibitors, 41.2% for sulfonylureas, and 36.7% for thiazolidinediones in a 238,000-patient MarketScan analysis.
- Poor adherence was associated with worse outcomes: among >11,000 veterans, MPR <80% was significantly associated with poor glycemic control (HbA1c >8%, P<0.001); in 1,198 survey respondents, each 1-point drop in self-reported adherence was linked to a 0.21% increase in HbA1c and increases of 4.6%, 20.4%, and 20.9% in physician, ER, and hospital visits.
- Mortality was higher with poor adherence: in 15,984 UK patients, poor adherence and missed visits were each associated with a 1.6-fold increase in all-cause mortality (P<0.001); another study reported an odds ratio of 1.8 (P<0.001).
- Economic impact was substantial: improved adherence was projected to reduce hospitalization/ER risk by 13%, worsening adherence to raise it by 15%, and one analysis estimated annual savings of $4.7 billion with improved adherence and $3.6 billion with reduced poor adherence.
## Methods
- Narrative review of the literature on medication adherence in T2D, focusing on the scope of the problem, consequences, key contributors, interventions, and future developments.
- The paper synthesizes findings from retrospective/observational claim-database studies, surveys, and meta-analyses; it cites examples including analyses of 238,000 MarketScan patients, >11,000 veterans, 1,198 survey respondents, and other large database studies.
- Main analysis is qualitative synthesis of reported adherence rates, outcomes, and modifiable contributors, with attention to common adherence metrics such as medication possession ratio (MPR) ≥80% and persistence definitions.
## Limitations
- The paper states that much of the evidence comes from retrospective or observational claim-database studies using widely varying definitions, making findings difficult to interpret.
- It states that intervention evidence is limited because adherence measures vary widely, hard outcomes are often lacking, interventions are not clearly explained, and follow-up is often inadequate.
- Evident from the text: this is a review, not a new primary study, so its conclusions depend on the quality and comparability of the cited literature.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 1 Not valid · 57 Not checked · 17 Own results and interpretations
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“In one study that tracked new prescriptions written electronically over a 12-month period for >75,000 patients, 31.4% of new prescriptions for diabetes drugs were never filled.25”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Scope of the problem
What the sources say
- Not matchedcites [25]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainn = 75,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common and is associated with inadequate glycemic control; increased morbidity and mortality; and increased costs of outpatient care, emergency room visits, hospitalization, and managing complications of diabetes.”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A statement the paper makes itself — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“perceived patient burden regarding obtaining and taking their medications (eg, treatment complexity, out-of-pocket costs, and hypoglycemia)”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Poor medication adherence in T2D is well documented to be very common”
§ Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors > Abstract
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
49 more claims
Create a free account to see all 75 claims and every source verdict.
- It may state two separate claims as one. 20
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple factors contribute to inconsistent medication use and treatment discontinuation among people with diabetes, including perceived lack of medication ef fi cacy, fear of hypoglycemia, lack of access to medication, and adverse effects of medication (63).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2DM who discontinue or do not properly adhere to their therapy, there is an increased risk of microvascular and macrovascular complications [7], which can in turn increase healthcare costs further [5, 6].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from this survey highlight patient perspectives on reasons for treatment discontinuation among people with T2DM in the USA and UK and provide focal points for communication for these individuals when they are initiating new therapies [5].”
From Understanding Reasons for Treatment Discontinuation, Attitudes and Education Needs Among People Who Discontinue Type 2 Diabetes Treatment: Results from an Online Patient Survey in the USA and UK (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the NICE guidance (NG28) and gastrointestinal tolerability are likely important drivers, early GLP‐1RA discontinuation is plausibly multifactorial and may also reflect perceived treatment effectiveness, complex dosing schedules, injection‐related barriers, limited access to diabetes education, economic constraints, and medication shortages. 19 , 32 , 33 , 34”
From Real‐world persistence and dose titration of GLP ‐1 receptor agonists in type 2 diabetes: A UK population‐based cohort study by obesity and cardiovascular disease status (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Up to 50% of people with T2DM discontinue treatment by 1 year [5].”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kirk, J., MacDonald, A., Lavender, P., Dean, J., & Rubin, G. (2017) · Biomedicine Hub · doi:10.1159/000480347 · Cited by 3,887
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Interventions for enhancing medication adherence
Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keepanasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., et al. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011.pub4 · Cited by 2,945 · cited 2×
“65 A key element is the need for greater consistency when measuring medication adherence, which require better instruments and tools for assessment.”
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Kennedy, L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70021-0 · Cited by 1,195
Ho, P. M., Rumsfeld, J. S., Masoudi, F. A., McClure, D. L., Plomondon, M. E., Steiner, J. F., & Magid, D. J. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1836 · Cited by 1,135
The Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“Even worse, it has been well documented that this cost burden has been inexorably growing worldwide.(10) A key contributor to the remarkably high rates of morbidity and mortality is chronic poor metabolic control, especially poor glycemic control.”
Adherence to Therapies in Patients with Type 2 Diabetes
García-Pérez, L.-E., Álvarez, M., Dilla, T., Gil-Guillén, V., & Orozco-Beltrán, D. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0034-y · Cited by 726 · cited 1×
“41 In their comprehensive review of 76 studies, Claxton et al 42 found that the prescribed number of doses per day was inversely associated with medication adherence; indeed, the mean adherence across studies decreased progressively from 79% with a once-daily dose to 51% with a four times daily…”
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationPrimary Medication Non-Adherence: Analysis of 195,930 Electronic Prescriptions
Fischer, M. A., Stedman, M. R., Lii, J., Vogeli, C., Shrank, W. H., Brookhart, M. A., & Weissman, J. S. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1253-9 · Cited by 572 · cited 1×
“25 This problem, often referred to as primary nonadherence, may be particularly relevant among patients who are refusing to initiate insulin or other injectable hypoglycemic therapy, typically due to injection phobia, inconvenience, poor patient–physician communication, and/or negative patient…”
Cited by
Items 401–500 of 761
Wysham, C., Rosenstock, J., Vetter, M. L., Wang, H., Hardy, E., & Iqbal, N. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000773 · Cited by 5
Cordioli, C., Callari, G., Fantozzi, R., Caruso, F., Martucci, G., Mascara, S., & Zipoli, V. (2021) · Neurological Sciences · doi:10.1007/s10072-020-04969-3 · Cited by 4
Alshayban, D., & Joseph, R. (2020) · PERIÓDICO TCHÊ QUÍMICA · doi:10.52571/ptq.v17.n34.2020.891_p34_pgs_867_873.pdf · Cited by 4
Food Security and Medication Adherence in Young and Middle-Aged Adults with Diabetes
Imel, B. E., & McClintock, H. F. D. V. (2021) · Behavioral Medicine · doi:10.1080/08964289.2021.1987855 · Cited by 4
Zhang, H., Huang, T., & Yan, T. (2021) · Health Care Management Science · doi:10.1007/s10729-021-09587-9 · Cited by 5
Tang, Y., Yan, J., Tang, L., & Liu, X. (2022) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2022.200128 · Cited by 4
“In addition, we find DM as a significant predictor of having ≥2 risk factors uncontrolled (Table 6) and a significant determinant of not receiving recommended medications (Table 7), which is in similar with a previous study reporting poor medication adherence in type 2 diabetes [49].”
ResultImproving Diabetes Care: A Fijian Diabetes Service Improvement Study
Ibrahim, A. M., & Lawrence, S. S. (2022) · International Journal of Chronic Diseases · doi:10.1155/2022/9486679 · Cited by 11
“Evidence suggests that lack of integrated care, clinical inertia amongst HCPs, low patient education levels, and their perceived beliefs about treatment inefficacy cause neglect in management [38].”
BackgroundEffectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management
Pham, T. T., Chen, X., Barron, J. O., Hart, R., Abarca, J., & DEVRIES, A. R. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14786 · Cited by 7
“As poor adherence contributes to poor glycaemic control, morbidity and mortality, affordable insulin is needed to ensure appropriate diabetes care.(3,6) Follow-on/biosimilar insulins present an opportunity to reduce costs and improve adherence.”
BackgroundMorello, C. M., Lai, L., Chen, C., Leung, C. M., Hirsch, J. D., & Bounthavong, M. (2022) · Pharmacy · doi:10.3390/pharmacy10030063 · Cited by 4
Davis, D. D., Hale, G. M., Moreau, C. S., Joseph, T., Pérez, A., & Rosario, E. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900221111144 · Cited by 6
Isaacs, D. M., Kruger, D. F., SHOGER, E., & Chawla, H. (2022) · Clinical Diabetes · doi:10.2337/cd22-0034 · Cited by 6
“Studies have shown that suboptimal adherence is closely linked to depression, diabetes-related distress, low treatment satisfaction, side effects, poor self-efficacy, and the overall burden of daily self-management with insulin therapy (33,34).”
BackgroundKoehler, J., Hildebrandt, O., Cassel, W., Conradt, R., Mayr, P., Alter, P. J., & Viniol, C. (2022) · Laryngo-Rhino-Otologie · doi:10.1055/a-1949-3026 · Cited by 6
“Diese Therapietreue ist zwar vergleichbar mit anderen Volkskrankheiten wie Hypertonie mit höchstens 60 % oder Diabetes mellitus Typ 2 um die 55% [9, 10], doch sollte man bestrebt sein, Gründe oder Auslöser von Therapiemüdigkeit aufzuzeigen.”
BackgroundLallemand, A., Verrue, C., Santi, A., Delhaye, N., Willaert, M., Attipoe, A., Tomas, M., & Philippe, G. (2023) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2023.100330 · Cited by 8
Zhang, Z., Du, C., Zhong, X., Wang, R., Tang, L., & Liu, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28239 · Cited by 5
“…analysis, we demonstrated that DM is an important influencing factor for multiple uncontrolled RFs and medication noncompliance ( OR = 2.27, CI : 1.79 – 2.87; OR = 0.47, CI: 0.34 – 0.67), which is consistent with a previous study that reported poor medication adherence in type 2 diabetes [28].”
BackgroundResultInfluentialTINSLEY, L. J., Wong, N. D., Reusch, J. E. B., Arnold, S. V., Kosiborod, M., Tang, Y., Laffel, L. M., & Mehta, S. N. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107591 · Cited by 4
Wehler, E., Lautsch, D., KOWAL, S. L., Davies, G., Briggs, A. H., Li, Q., Rajpathak, S. N., & Alsumali, A. (2020) · PharmacoEconomics · doi:10.1007/s40273-020-00967-7 · Cited by 5
Emoto, N., Soga, A., Fukuda, I., Tanimura‐Inagaki, K., Harada, T., Koyano, H. M., Goto, R., & Sugihara, H. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s283591 · Cited by 4
Platis, C. G., Spanou, A., Messaropoulos, P., et al. (2020) · WSEAS TRANSACTIONS ON BIOLOGY AND BIOMEDICINE · doi:10.37394/23208.2020.17.5 · Cited by 4
Miller, M. J., DiNucci, A. J., Jalalzai, R., Rabinovich, N., & Roblin, D. W. (2022) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxac056 · Cited by 4
Adolescent and Caregiver Perspectives on Provider–Patient Interactions in Type 2 Diabetes
Amirniroumand, R., Valenzuela, J. M., SMITH, L. B., Nicholl, M. C., Dolan, L. M., & Powers, S. W. (2017) · Clinical Practice in Pediatric Psychology · doi:10.1037/cpp0000213 · Cited by 4
“However, adherence to intensive treatment regimens for T2D is poor (Polonsky & Henry, 2016).”
BackgroundChoosing the Best Oral Diabetic Agents in T2 Diabetes Mellitus-Physicians Challenge
Mohanty, B. (2018) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000797 · Cited by 3
“A recent review article by Polonsky and Henry proposed that the reasons come down to six factors [53].”
BackgroundPrediction of new prescription requirements for diabetes patients using big data technologies
Bakırarar, B., Yüksel, C., & Yavuz, Y. (2021) · Journal of Health Research · doi:10.1108/jhr-05-2020-0136 · Cited by 4
Guideline Development for Medical Device Technology: Issues for Consideration
Battelino, T., Brosius, F. C., Ceriello, A., Cosentino, F., Green, J., Kellerer, M., Koob, S., Kosiborod, M., Lalic, N. M., Marx, N., et al. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221093355 · Cited by 5
Joho, A. A., Sandi, F., & Yahaya, J. J. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001351 · Cited by 8
Verma, S., Mohanty, I. R., & Rai, S. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_64_23 · Cited by 5
Hadush, F., Gebretekle, G. B., Kahissay, M. H., et al. (2024) · Journal of Diabetes Research · doi:10.1155/2024/3652855 · Cited by 3
“Yet, despite the availability of e ff ective glucose-lowering medication, approximately 45% of T2DM patients exhibit poor glycemic control, with medication nonadherence playing a substantial contributory role [3].”
Jannah, W., Khoiry, Q. A., Alfian, S. D., & Abdulah, R. (2025) · Patient Preference and Adherence · doi:10.2147/ppa.s492461 · Cited by 11
Elayyan, B., Abuhalima, D., Al‐Jabi, S. W., & Zyoud, S. H. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02000-4 · Cited by 5
Chodapuneedi, S., Koh, J. W., Orman, Z., Gašević, D., Magliano, D. J., Zoungas, S., Hamblin, P. S., Trin, C., Zomer, E., Cataldo-Miranda, P., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112409 · Cited by 3
Barriers to effective management of type 2 diabetes mellitus in primary healthcare facilities
Mogale, N. M., Ntuli, T. S., & Chelule, P. K. (2025) · Journal of Public Health in Africa · doi:10.4102/jphia.v16i1.1420 · Cited by 5
Abdullahi, M. I., Bi, Y., Wang, M., Ashiru, M. H., Zheng, Z., & Jin, Y. (2025) · Global Health Research and Policy · doi:10.1186/s41256-025-00427-9 · Cited by 6
Liu, X., Varshney, U., & Li, P. (2025) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaf199 · Cited by 5
Arshed, M., Kiran, M., Ashraf, W., Virk, M. K. S., Qamer, S., Umer, M. F., Umar, A., Saleem, J., Gillani, A. H., Hanif, A., et al. (2025) · BMC Public Health · doi:10.1186/s12889-025-25031-x · Cited by 12
“Additionally, treatment complexity, high costs, adverse effects, polypharmacy, and complicated dosing schedules can impede adherence [15, 17].”
InfluentialSemotiuk, A., Hernández-Romano, E. F., Colunga-Garcíamarín, P., Salazar-Olivo, L., & Ezcurra, E. (2020) · Journal of Herbal Medicine · doi:10.1016/j.hermed.2020.100354 · Cited by 4
Krejany, C., Kanjo, E., Gaedtke, L., Chakera, A., & Jiwa, M. (2021) · Endocrine · doi:10.1007/s12020-021-02771-5 · Cited by 4
Adherence to Hypoglycemic Agents in Type 2 Diabetes Mellitus: A Cross-Sectional Study
Khayyat, Y. A., Alshamrani, R., Bintalib, D. M., Alzahrani, N. A., & Alqutub, S. T. (2022) · Cureus · doi:10.7759/cureus.22626 · Cited by 4
First-in-Class Oral Semaglutide: Overcoming Barriers of Incretinisation in the Indian Context
Rajput, R., Ghosh, S., Banerjee, S., Bansal, B., Chawla, M. S., Ahluwalia, A. I., Lathia, T. B., & Das, A. K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_217_22 · Cited by 3
Vay‐Demouy, J., Vallée, A., Cinaud, A., Lelong, H., Kretz, S., Blachier, V., Sorbets, E., & Blacher, J. (2023) · Trials · doi:10.1186/s13063-023-07437-3 · Cited by 4
“This rate is similar for all the main CV risk factors, such as type 2 diabetes and dyslipidemia [8,9].”
BackgroundWhat Is the Role of Basal Weekly Insulin in Clinical Practice? The State of the Art
Argano, C., Priola, L., Manno, F., & Corrao, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040900 · Cited by 5
“Problems related to therapeutic adherence, quality of life, hypoglycemic risk and secondary disability or the expected compensation often arise [30].”
BackgroundLin, Y.-W., Chen, P., Lin, C.-H., & Lin, M.-H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0304442 · Cited by 4
“…pressure-related diseases are major causes of death [9] Adher-ent diabetes patients experience reduced hospitalization rates and healthcare costs [10,11] Generally, enhanced medication adherence is linked to reduced hospitalization and ICU admission rates as well as fewer healthcare costs [12].”
BackgroundWu, Y., Xiong, S., Zhu, G., et al. (2024) · Exploratory Research in Clinical and Social Pharmacy · doi:10.1016/j.rcsop.2024.100482 · Cited by 3
NARWAT, A., GOYAL, A., & Bhati, R. K. (2024) · International Journal of Current Pharmaceutical Research · doi:10.22159/ijcpr.2024v16i6.5091 · Cited by 4
“Indeed, poor medication adherence is one of the most common causes of emergency room visits, hospitalization, enhanced morbidity and mortality, and increased costs of care in patients with T2D [4].”
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Rana, P., Vestergaard, P., & Hangaard, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112191 · Cited by 4
Clinical Profile of Patients with Diabetes Mellitus in Gusau, Northwestern, Nigeria
Sada, K. B., Sabir, A. A., Sakajiki, A. M., Umar, M. T., Abdullahi, U., & Sikiru, Y. A. (2021) · Annals of African Medicine · doi:10.4103/aam.aam_16_20 · Cited by 7
“[8] Many studies have reported poor glycemic control among patients with DM Worldwide and most especially in resource-poor countries.”
Why Do Mental Disorders Persist? Evolutionary Foundations for Psychiatry
Nesse, R. M. (2021) · Cambridge University Press eBooks · doi:10.1017/9781911623625.008 · Cited by 4
Brod, M. I., Waldman, L. T., Sparre, T., & Busk, A. K. (2022) · Journal of Diabetes Science and Technology · doi:10.1177/19322968221079396 · Cited by 3
Mohammad, I., George, J., Zimmerman, J., & Elteriefi, R. (2022) · INNOVATIONS in pharmacy · doi:10.24926/iip.v13i2.4815 · Cited by 5
Rajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
“Factors that may affect medication adherence include, but are not limited to, frequency of administration, side effects, efficacy, device type, and affordability [69].”
BackgroundPantalone, K. M., Rajpathak, S. N., Ji, X., Jin, J., Weiss, T., Bauman, J. M., Radivoyevitch, T., Kattan, M. W., Zimmerman, R. S., & Misra‐Hebert, A. D. (2022) · Diabetes Spectrum · doi:10.2337/ds22-0031 · Cited by 3
“Poor medication adherence is a well-known barrier to A1C goal attainment in patients with type 2 diabetes (16).”
BackgroundKhan, A. H., Iqbal, M. Z., Sulaiman, S. A. S., Ibrahim, A., Azmi, N. S. B. Y., & Iqbal, M. S. (2021) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres20.927_9.2.153 · Cited by 3
“Patient compliance can be increased with appropriate counseling and education of patients about the consequences of uncontrolled disease by healthcare providers (Polonsky and Henry, 2016).”
BackgroundAshik, T., Lee, V., Atanes, P., & Persaud, S. J. (2022) · Diabetic Medicine · doi:10.1111/dme.14978 · Cited by 2
Talaat, S. M. (2023) · ARO-The Scientific Journal of Koya University · doi:10.14500/aro.11041 · Cited by 3
Khachian, A., Seyedfatemi, N., Nia, H. S., & Amiri, M. (2022) · Iran Journal of Nursing · doi:10.32598/ijn.35.137.3084 · Cited by 5
Benito‐Garcia, E., Vega, J., Daza, E. J., Lee, W.-N., Kennedy, A., & CHANTELOT, J.-M. (2023) · JMIR Formative Research · doi:10.2196/47145 · Cited by 3
“Such collaborations have been shown to play a role in both adherence to and continuation of diabetes treatments [13,14], which in turn improves outcomes.”
BackgroundRavi, S., Meyerowitz‐Katz, G., Murugesan, A., Ayre, J., Jayaballa, R., Rintoul, D., Sarkis, M., McCaffery, K. J., MABERLY, G. F., & Bonner, C. (2024) · International Journal of Integrated Care · doi:10.5334/ijic.7548 · Cited by 3
Crosswell, R., Norman, K., Cassim, S., Papa, V., Keenan, R., Paul, R. G., & Chepulis, L. M. (2024) · Journal of Primary Health Care · doi:10.1071/hc23141 · Cited by 3
“It has been identified that the quality of communication and information during this time is directly associated with medication adherence 29 and self-management of their disease 30 and, therefore, overall diabetes management.”
BackgroundHajati, E., Gharraee, B., Lavasani, F. F., Farahani, H., & Rajab, A. (2024) · Journal of Behavioral Medicine · doi:10.1007/s10865-024-00507-0 · Cited by 8
“%) are unable to maintain satisfactory HbA1c control (HbA1c < 7%; Polonsky & Henry, 2016 ).”
InfluentialAl-Chawishli, S., Dizaye, K. F., & Azeez, S. S. (2024) · Cureus · doi:10.7759/cureus.70397 · Cited by 9
“Studies estimate that poor medication adherence accounts for 30% to 50% of T2D treatment failures, representing a major barrier to effective disease management [4,7,12].”
BackgroundRELAÇÃO ENTRE O LETRAMENTO EM SAÚDE E A ADESÃO TERAPÊUTICA DE PACIENTES COM DIABETES MELLITUS TIPO 2
Blacher, P. H., Mendonça, I. R., Vieira, C. S., et al. (2022) · Arquivos Catarinenses de Medicina · doi:10.63845/esyk0n54 · Cited by 3
Predictors of insulin adherence among patients with type 2 diabetes: a cross-sectional study
Muhammad, H. J., Hussein, R. M., Zmezim, M., Al‐Hussainy, A. F., Farhood, H. H., Naser, I. H., & Alghurabi, H. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2517697 · Cited by 7
“This finding contrasts with previous studies, where age has often been shown as a significant factor, with younger patients frequently reported as less adherent due to challenges such as reduced perceived vulnerability or lifestyle factors conflicting with medication adherence 15,19 .”
Butt, M., Ali, A. M., & Makmor‐Bakry, M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180828152754 · Cited by 3
Raza, S., Iqbal, Q., Haider, S., Khalid, A., Hassali, M. A., & Saleem, F. (2019) · Journal of Public Health · doi:10.1007/s10389-019-01046-8 · Cited by 3
Ipingbemi, A. E., & Erhun, W. O. (2021) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v18i4.27 · Cited by 4
“Adherence with medication therapy is generally low among patients with chronic conditions such as diabetes [6].”
BackgroundLeto, G., Barchetta, I., Candia, L. D., Magotti, M. G., Cianciullo, M., Manti, R., Negri, C., Cimino, V., Dodesini, A. R., Zerella, F., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01137-4 · Cited by 5
“any medication regimen requiring more than once-daily dosing [46].”
BackgroundGorbacheva, A. M., Logvinova, O., & Mokrysheva, N. (2022) · Problems of Endocrinology · doi:10.14341/probl13088 · Cited by 3
The revalidation of the diabetes treatment-related quality-of-life (DTR-QOL) questionnaire in Japan
Ishii, H., Kim, H. R., & Crawford, B. (2018) · Diabetology International · doi:10.1007/s13340-018-0371-1 · Cited by 3
George, M., Fathima, F., George, N. S., Mathew, S. S., Rajitha, M., Agrawal, T., & Kasturi, A. (2019) · Indian Journal of Community Medicine · doi:10.4103/ijcm.ijcm_231_18 · Cited by 6
Romera, I., Conget, I., Vázquez, L. A., Gentilella, R., Lebrec, J., Jódar, E., & Reviriego, J. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107575 · Cited by 3
Weir (2020) · The Journal of Family Practice · doi:10.12788/jfp.0068 · Cited by 3
Recognition and Management of Hypoglycemia
Shubrook (2020) · The Journal of Family Practice · doi:10.12788/jfp.0069 · Cited by 3
Booklet handout to improve glycemic control in type-2-DM patients and comparison with other models
Viviandhari, D., Wulandari, N., & Rahmi, N. (2021) · Pharmaciana · doi:10.12928/pharmaciana.v11i1.17511 · Cited by 4
Achouri, M. Y., Tounsi, F., Messaoud, M., Senoussaoui, A., & Abdelaziz, A. B. (2021) · PubMed Central · Cited by 18
Mpila, D. A., Wiyono, W. I., & Lolo, W. A. (2023) · Medical Scope Journal · doi:10.35790/msj.v6i1.51696 · Cited by 27
Polhuis, K. C. M. M. (2023) · doi:10.18174/631882 · Cited by 5
Factors Associated with Achieving HbA1c Targets in Patients with Type 2 Diabetes
Mehrabbeik, A., Tofighi, D., Khalilzadeh, S. H., Azizi, R., Namiranian, N., & Azad, F. (2024) · Jundishapur Journal of Chronic Disease Care · doi:10.5812/jjcdc-147903 · Cited by 4
Shah, S., Barot, P. A., Patel, H., et al. (2025) · Cureus · doi:10.7759/cureus.78391 · Cited by 2
“Poor medication adherence can diminish the effectiveness of therapeutic interventions, resulting in inadequate glycemic control, prolonged hospitalizations, and substantial financial burdens on patients and healthcare systems [6].”
Negussie, Y. M., & Abebe, A. T. (2025) · Scientific Reports · doi:10.1038/s41598-025-97909-0 · Cited by 8
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., Fatima, B., & Abughosh, S. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109080 · Cited by 2
Assessment to barriers of medication adherence among patients with Type 2 Diabetes Mellitus
Alfian, R., Ariani, N., Nita, Y., & Athiyah, U. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1693752 · Cited by 6
Exploring diabetic patients experiences during war in Sudan: insights from a multi-city study
Alamin, M. H., Mamoun, M., Elomeiri, L. E. S. M. A., Osman, S. H. M., Abdou, S. M., Yasin, F. M. O., Mohamed, E. A. M., Idris, A. A., Ahmed, M., Ahmed, L. A. A. M., et al. (2025) · Conflict and Health · doi:10.1186/s13031-025-00671-3 · Cited by 2
“All these behaviors are quite hazardous as they alter the glycemic control, increase the risk of complications and thus adversely affect their long-term health outcomes [37, 38].”
Holdt‐Caspersen, N. S., Dethlefsen, C., Hejlesen, O. K., Christiansen, E., Hangaard, S., Vestergaard, P., & Jensen, M. H. (2025) · JMIR Research Protocols · doi:10.2196/64899 · Cited by 3
“The patients’ preferences on the side effect profile, perceived complexity of the treatment, and the route of administration may all be barriers to good adherence [9-11].”
Understanding insulin dose deviations in people with type 2 diabetes receiving telemonitoring
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Vestergaard, P., & Hangaard, S. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.10.001 · Cited by 2
Clarifying the real challenge: adherence, not efficacy, is the barrier to exercise as medicine
MacDonald, C., Bennekou, M., Midtgaard, J., Langberg, H., & Lieberman, D. E. (2025) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-110988 · Cited by 3
“32 Adherence to oral glucose-lowering agents varies widely, from 36% to 93%, depending on treatment duration, population and adherence definitions.”
Gauld, N. J., Faletau, J., Bentley, M. L., & Tutty, S. (2025) · Journal of Primary Health Care · doi:10.1071/hc25123 · Cited by 2
Bjornstad, P., Danne, T., KLINGENSMITH, G. J., Schueler, E., Tartakovsky, I. S., Marquard, J., Zeitler, P. S., Willi, S. M., & Laffel, L. M. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000889 · Cited by 2
“13 As a result, there is an urgent need for improved and tolerable treatment options.”
Mai, Z., Kornak, J., Dufault, S. M., Strand, M. W., Reikes, A., & Watanabe, J. H. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251384637 · Cited by 2
Gama, F. D. S., Ferreira, M. A., Segretti, N., Damião, M. C. F. C. B., Guimarães, C. R. W., Mascarello, A., & de Azevedo, H. F. Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02225 · Cited by 4
Mokgalaboni, K., Ahmed, S. R., Phoswa, W. N., Mashaba, G. R., Mokgalabone, T. T., Ndhlala, A. R., Mpai, S., & Lebelo, S. L. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100451 · Cited by 6
“Although standard treatments are available, access is limited, and adherence is often unsatisfactory, particularly in low-and middle-income countries [11 – 16].”
Mucherino, S., Orlando, V., Vervloet, M., Weesie, Y. M., van Dijk, L., & Menditto, E. (2026) · PLoS ONE · doi:10.1371/journal.pone.0342056 · Cited by 2
Grundlagen des Diabetesmanagements
Kulzer, B., Aberle, J., Haak, T., Kaltheuner, M., Kröger, J., Landgraf, R., & Kellerer, M. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1916-2262 · Cited by 2
Chen, J., Fan, L., Maughn, K., Rey, G. G., Liu, Y., Nelson, D. R., & Hood, R. C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15022 · Cited by 3
“At the patient level, therapeutic inertia can include noncompliance with treatment, missing of appointments, including HbA1c test visits, the failure to selfmonitor blood glucose, burdens of treatment, or psychological resistance to insulin (eg, anxiety related to medication side effects or injections).(21) In additio…”
BackgroundRole of pharmaceutical care in therapeutic regimens within the community pharmacy
Filotheidou, A., Theodosis‐Nobelos, P., & Triantis, C. (2023) · Česká a slovenská farmacie · doi:10.5817/csf2023-2-70 · Cited by 6
Munshi, M. N., Ritzel, R. A., Jude, E. B., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15377 · Cited by 2
“20 Furthermore, as prandial insulin analogues contain rapid or intermediate-acting insulin analogues associated with considerable glycaemic variability, there is a relatively high risk of hypoglycaemia.”
BackgroundTamuhla, T., Raubenheimer, P. J., Dave, J. A., & Tiffin, N. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002730 · Cited by 2
Jain, S. N., Choi, J. Y., Cooper, B., Renwick, B., Mohamed, M. M., & Makris, S. A. (2024) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2023.11.035 · Cited by 2
Vallis, M., Jin, S., Klimek-Abercrombie, A. M., Ng, G., & Ivers, N. M. (2024) · Diabetes Spectrum · doi:10.2337/ds23-0038 · Cited by 5
“Polonsky and Henry (4) emphasized that innovative strategies to improve the attitudes of people with type 2 diabetes toward medication or encourage habit formation regarding medication-taking may help increase engagement.”
BackgroundInfluentialBelhaj, H., Barouaca, H., Oudghiri, D. E., Lamiri, A., Mostakim, M., Timihiri, A., Ahyayauch, H., & Younes, S. (2024) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2024.1.28 · Cited by 6
Dwiyatna, S., Suprapti, B., Nilamsari, W. P., Nugroho, C. W., & Ardiana, S. M. (2024) · Pharmacia · doi:10.3897/pharmacia.71.e117126 · Cited by 8
Omotosho, T. O. A., & Senghore, T. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s464761 · Cited by 2
Metadata
- Authors
- Polonsky, W., & Henry, R.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Polonsky, William
- Venue
- Patient Preference and Adherence
- Publisher
- Informa UK Limited
- Published
- 2016-07
- Volume
- Volume 10
- Pages
- 1299-1307
- ISSN
- 1177-889X (ISSN-L)
- PMC
- PMC4966497
- OpenAlex
- W2493860075
- Cited by
- 784
- References
- 77
- Citations by year
- 2026: 93 · 2025: 97 · 2024: 89 · 2023: 82 · 2022: 108 · 2021: 106 · 2020: 106 · 2019: 54 · 2018: 34 · 2017: 13 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Patient Preference and Adherence (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Intarcia Therapeutics
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- medication adherence, type 2 diabetes, glycemic control, barriers to adherence, medication beliefs, medication burden, out-of-pocket costs, hypoglycemia, treatment complexity, clinical inertia, socioeconomic factors, diabetes complications, drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.